Takeda launches prognostic Crohn’s disease blood test

Biopharmaceutical company Takeda has announced the launch of its Cdpath program, which uses a blood test to predict someone's risk for developing Crohn's disease within the next three years, according to a Sept. 14 press release sent to Becker's.  

Read the full post at Becker's ASC
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive